Share Icon Health Study Area: Cardiovascular Disease Chevron Icon Health Study Area: Genitourinary For Patients Health Study Area: Lung Cancer Page Icon Phone Icon For Caregivers Health Study Area: AutoImmune Disease Health Study Area: Melanoma Location Icon Print YouTube Icon For Parents Health Study Area: Lung Cancer Print Created with Sketch. Help Icon Green Check Icon Search Icon Instagram Created with sketchtool. Direction Arrow Icon Error Icon For Parents Health Study Area: Blood Cancer Help Icon Health Study Area: NASH Gender Both Bookmark Icon Health Study Area: Melanoma Created with Sketch. Glossary Print Health Study Area: Blood Cancer Health Study Area: Genitourinary Health Study Area: Gastrointestinal Cancer Mobile Menu Icon Created with Sketch. Health Study Area: Cardiovascular Disease Health Study Area: Women's Cancer Communities Map Icon Created with Sketch. For Caregivers Health Study Area: Fibrosis Health Study Area: AutoImmune Disease FAQs Health Study Area: Head and Neck Cancer Created with Sketch. For Clinicians Chevron Right Icon Gender Female Health Study Area: Breast Cancer Direction Arrow Icon Gender Both Right Arrow Icon LinkedIn Icon Green Check Icon Gender Male Health Study Area: Fibrosis For Patients Twitter Icon Email Icon Facebook Icon Health Study Area: Gastrointestinal Cancer Health Study Area: Head and Neck Cancer For Clinicians External Link Icon

Menü

Klinische Studien von BMS suchen
BMS-Symbol für "Aktive Studie, für die noch nicht rekrutiert wird"

Active, Not Recruiting

Studien-Nr. CN009-1024  |   NCT06144697

A Study to Evaluate the Safety, Tolerability, Drug Levels, Food, Formulation, and pH Effects on Relative Absorption of BMS-986465 and Its Active Derivative BMS-986464 in Healthy Participants

Warnsymbol
In diese Studie werden leider keine neuen Patient:innen aufgenommen, sie ist aber weiterhin aktiv.
Sie können auf die Schaltfläche "Prüfen Sie, ob eine Studie für Sie infrage kommt“ und einige Fragen zu Ihrer Gesundheit beantworten, um herauszufinden, ob eine andere Studie für Sie infrage kommt.
Kommt die Studie für Sie infrage

Zusammenfassung

  • Phase 1
  • Symbol für männliches und weibliches Geschlecht
  • 18-55
    Altersgruppe
  • BMS-Symbol für "Aktive Studie, für die noch nicht rekrutiert wird"
    Active, Not Recruiting

Überblick

The purpose of this study is to evaluate safety, tolerability, drug and food effects on relative bioavailability of BMS-986465 and its active derivative BMS-986464 in healthy participants and healthy participants of Japanese ethnicity.

Druckmedium-alt Druckmedium
email E-Mail

Wichtigste Einschlusskriterien

Inclusion Criteria: - Healthy male and female (i e, women not of childbearing potential) participants - Body Mass Index (BMI) of 18 to 32 kg^m2 and total body weight ≥ 50 kg - Parts A, B, and D: Participants without restriction on ethnicity - Part C: Participants of Japanese ethnicity (both biological parents are ethnically Japanese) Exclusion Criteria: - Clinically significant medical, psychiatric and/or sound social reason, as determined by the investigator - Any major surgery within 3 months of study intervention administration - Participation in another clinical trial concurrent with this study Note: Other protocol-defined inclusion/exclusion criteria apply

Behandlungsmöglichkeiten

Studienarme

ZUGEWIESENE BEHANDLUNG

Studienarme

Experimental: Part A: Single Ascending Dose (SAD) [BMS-986465 or placebo]

ZUGEWIESENE BEHANDLUNG
  • Drug: BMS-986465
  • Other: Placebo

Studienarme

Experimental: Part B: Multiple Ascending Dose (MAD) [BMS-986465 or placebo, Pegasys]

ZUGEWIESENE BEHANDLUNG

Studienarme

Experimental: Part C: MAD in Japanese ethnicity [BMS-986465 or placebo]

ZUGEWIESENE BEHANDLUNG
  • Drug: BMS-986465
  • Other: Placebo

Studienarme

Experimental: Part D: Food/Formulation/pH Effects [BMS-986465, Famotidine]

ZUGEWIESENE BEHANDLUNG

Unterstützen Sie uns dabei, Ihre Nutzung der Website zu optimieren! Teilen Sie Ihr Feedback mit unserem Team bei BMS Clinical Trials, um die Nutzung der Webseite, Ihre Erfahrungen und die anderer zu verbessern. Vielen Dank!